The use of Lamiktal in treating epilepsy in children and adolescents

Antiepileptic effects of lamiktal (lamotrigine) produced in Great Britain (Wellcome) was tried in 7 children aged 3-14 and 3 adults aged 18-30. Of them 6 patients and 4 patients suffered from temporal polymorphic fits and general paroxysms, respectively. Upon 3-month follow-up it was found that the fits discontinued in 4 patients, frequency of the paroxysms reduced or they became abortive in 6 cases. EEG changes were insignificant. No side effects occurred. Lamiktal is recommended in polymorphic seizures in children and adults, in failure of other anticonvulsants in patients frequently affected with epileptic paroxysms.